91 related articles for article (PubMed ID: 19158446)
21. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
22. Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer.
Asola R; Huhtala H; Holli K
Breast Cancer Res Treat; 2006 Nov; 100(1):77-82. PubMed ID: 16758120
[TBL] [Abstract][Full Text] [Related]
23. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
24. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Ewer MS; Glück S
Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
[TBL] [Abstract][Full Text] [Related]
25. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
26. The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study.
So WK; Marsh G; Ling WM; Leung FY; Lo JC; Yeung M; Li GK
Oncol Nurs Forum; 2009 Jul; 36(4):E205-14. PubMed ID: 19581224
[TBL] [Abstract][Full Text] [Related]
27. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
28. A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
Burdette-Radoux S; Muss HB
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S37-41. PubMed ID: 19561005
[TBL] [Abstract][Full Text] [Related]
29. Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer.
Tiezzi DG; de Andrade JM; Marana HR; Garieri AP; de Paula Philbert PM
Breast J; 2009; 15(4):333-8. PubMed ID: 19496783
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
McArthur HL; Gelmon KA; Olivotto IA; Speers CH; Ellard SL; O'Reilly SE; Kennecke HF
J Clin Oncol; 2009 Mar; 27(9):1388-93. PubMed ID: 19237634
[TBL] [Abstract][Full Text] [Related]
31. [An index of understanding randomised clinical trials in oncology].
Leroy T; Christophe V; Penel N; Antoine P; Vanlemmens L; Reich M; Clisant S
Bull Cancer; 2009 Jun; 96(6):741-50. PubMed ID: 19467958
[TBL] [Abstract][Full Text] [Related]
32. [Quality of life of patients with breast cancer receiving hormonal therapy, depending on age and marital status].
Trishikina EA; Orlova RV; Roman LD
Vopr Onkol; 2009; 55(3):310-3. PubMed ID: 19670730
[TBL] [Abstract][Full Text] [Related]
33. PET-CT in recurrent head neck cancers: a study to evaluate impact on patient management.
Pantvaidya GH; Agarwal JP; Deshpande MS; Rangarajan V; Singh V; Kakade A; D'Cruz AK
J Surg Oncol; 2009 Oct; 100(5):401-3. PubMed ID: 19235784
[TBL] [Abstract][Full Text] [Related]
34. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
35. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy for locally advanced breast cancer.
Specht J; Gralow JR
Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
[TBL] [Abstract][Full Text] [Related]
37. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography.
Malone JP; Gerberi MA; Vasireddy S; Hughes LF; Rao K; Shevlin B; Kuhn M; Collette D; Tennenhouse J; Robbins KT
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1119-25. PubMed ID: 19917925
[TBL] [Abstract][Full Text] [Related]
38. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
[TBL] [Abstract][Full Text] [Related]
39. Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey.
Luschin G; Habersack M
Health Commun; 2014; 29(4):421-6. PubMed ID: 23537378
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
